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Sir,
Extrapolating from our findings that mRNA for the dermcidin
gene (Schittek et al, 2001), which encodes the proteolysis-inducing
factor (PIF) core peptide (PIF-CP), is present in both gastro-
oesophageal tumour and adjacent non-tumour tissue, EA Rapoport
suggests that PIF may be generally involved in muscle breakdown
via production of PIF in tissues requiring amino acids for tissue
regeneration, for example, in liver regeneration. There are,
however, several caveats, which need to be applied to this
suggestion. The first is that it is only the glycosylated form of
the PIF-CP that has been shown to induce muscle breakdown
(Todorov et al, 1996), and this form is difficult to identify in
tissues (Wieland et al, 2007). Glycosylated PIF has also been shown
to have pro-inflammatory effects on hepatocytes (Watchorn et al,
2001) and other cell types. In our study (Deans et al, 2006), we
made no claim that glycosylated PIF was present in gastro-
oesophageal tumours or adjacent tissues. In addition, the PIF-CP is
homologous to a neural survival peptide (YP-30) (Cunningham
et al, 2002), and expression of the gene encoding the PIF-CP has
been shown to provide a small survival and proliferative advantage
to other cell types including tumours (Lowrie et al, 2006, and
Stewart et al, 2007). Furthermore, evidence suggests that the
YP-30/PIF-CP peptide may have a role in development, acting as a
maternal blood-borne factor, which promotes survival of the
developing thalamus (Landgraf et al, 2005). In a recent development,
there is now evidence that peptide products of the dermcidin gene
may participate in the regulation of placental function by means
of modulating proteolytic cascades on the trophoblastic surface
(Motoyama et al, 2007) and having proteolytic activity. Therefore,
while EA Rapoport’s suggestion may be unlikely in the light of
present evidence, there is still much to be discovered about this
fascinating gene and its products.
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